• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Aptorum Group Limited

    12/21/23 4:30:33 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APM alert in real time by email
    6-K 1 ea190482-6k_aptorum.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K 

      

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2023

     

    Commission File Number: 001-38764

      

    APTORUM GROUP LIMITED

     

    17 Hanover Square

    London W1S 1BN, United Kingdom

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    On December 20, 2023, Aptorum Group Limited (the “Company”) held its 2023 annual meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on two proposals. At the beginning of the Annual Meeting, there were 206,711,322 votes represented in person or by proxy, which represented approximately 90.93% of the voting power of the shares entitled to vote at the Annual Meeting; a quorum was presented for the transaction of business.

     

    We are filing this Current Report on Form 6-K to disclose the voting results from the Annual Meeting. The following proposals were voted on:

     

    1.To re-elect all Class I directors to the Company’s board of directors (the “Board”) until the third annual meeting of shareholders or until his/her respective successor is elected and duly qualified; and.

     

    Name  For   Against   Abstain/Withheld 
    Mr. Charles Bathurst   206,699,393    8,159    3,770 
    Dr. Mirko Scherer   206,699,831    7,974    3,517 
    Professor Justin Wu   206,683,588    24,019    3,715 
    Professor Douglas Arner   206,661,036    46,517    3,769 

     

    2.To approve, ratify and confirm the re-appointment of Marcum Asia CPAs LLP as the Company’s independent auditors for the year ending December 31, 2023, and to authorize the Board of Directors to fix their remuneration.

     

    For   Against   Abstain 
     206,703,950    1,769    5,603 

     

    There were no broker non-votes for either proposal.

     

    On December 21, 2023, the Company issued a press release announcing the results of the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.

     

    The information in this Form 6-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

     

    This Form 6-K is hereby incorporated by reference into the registration statements of the Company on Form S-8 (Registration Number 333-232591) and Form F-3 (Registration Number 333-268873) and into each prospectus outstanding under the foregoing registration statements, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

     

    1

     

     

    EXHIBIT INDEX

      

    Exhibit No.   Description
    99.1   Press Release

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Aptorum Group Limited
         
    Date: December 21, 2023 By: /s/ Ian Huen
        Name:  Ian Huen
        Title: CEO

     

     

    3

     

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APM
    SEC Filings

    View All

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    2/6/26 4:00:16 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    1/21/26 7:01:11 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-4/A filed by Aptorum Group Limited

    S-4/A - Aptorum Group Ltd (0001734005) (Filer)

    1/21/26 5:17:16 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

    NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. ("INB"), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB's automated APOE testin

    2/2/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

    NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. Details

    11/19/25 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

    $2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 Class A ordinary shares at a purchase price of $2.00 per share in a registered direct offering. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per s

    10/10/25 9:54:01 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

    SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

    4/16/24 4:32:40 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aptorum Group Limited (Amendment)

    SC 13G/A - Aptorum Group Ltd (0001734005) (Subject)

    2/2/24 4:02:58 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Aptorum Group Limited (Amendment)

    SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)

    5/24/23 9:00:21 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    Leadership Updates

    Live Leadership Updates

    View All

    Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

    Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors

    12/21/23 4:30:00 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

    Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly know

    12/22/22 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

    Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, which was held on December 2, 2021, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: Re-elected all of the Company's current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the Company's next annual general meeting o

    12/3/21 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    Financials

    Live finance-specific insights

    View All

    Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

    Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

    12/20/24 4:00:00 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

    Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing

    12/22/23 4:30:00 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

    ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years

    3/17/23 8:15:00 AM ET
    $APM
    $ASPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials